A Case For List Price Cuts? Study Highlights Reduced 340B Liability For Hep C Drugs
Lower list prices for Epclusa, Harvoni, and Zepatier might actually boost revenue by reducing 340B discounts, but rebate-eschewing dynamic may not expand beyond them because of different exposures to 340B in other classes – and the pending HHS rebate rule.
You may also be interested in...
Policymakers should clarify link between high drug prices and innovation and figure out how to “rebalance” high prices with non-price innovation incentives before proceeding with policies aimed directly at lowering prices, Conti and David propose in the Health Affairs Blog.
Approach has been endorsed by Express Scripts as more workable solution than trying to cut list prices for drugs already on the market.
A 60% price reduction on hepatitis C drug Zepatier sounds impressive, but the drug has been declining and the HCV space overall is shrinking. Another set of 10% reductions come on small-sellers that are now generic.